Taha Koray Sahin: Myosteatosis in ICI-treated patients

Taha Koray Sahin shared a post on X, about recent paper published in Clinical Nutrition ESPEN:

Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis.

Authors: Taha Koray Sahin, Deniz Can Güven.

”Our new article is now published in Clinical Nutrition ESPEN. Eleven studies including over 1300 patients. Overall survival (OS) and progression-free survival (PFS) with myosteatosis in ICI-treated patients. A promising biomarker.”

Deniz Can Guven shared a post by Taha Koray Sahin on X, adding:

”Another important paper by the rising star of Hacettepe University. Congratulations Taha Koray Sahin. Humbled to be a mentor for him and watch him grow. Stay tuned for his future work.”

Source: Taha Koray Sahin/X and Deniz Can Guven/X

Taha Koray Sahin is an oncology researcher at Hacettepe University in Türkiye. His research focuses on developing new methods for cancer diagnosis and treatment, contributing to advancements in cancer therapy and patient care.

Deniz Can Güven is an oncologist at Hacettepe University Cancer Institute in Türkiye. He serves as a member of the ESMO Young Oncologists Committee and represents young oncologists within the Turkish Society of Medical Oncology.